ARQT · Arcutis Biotherapeutics, Inc.
$26.19
+0.36 (+1.39%)
At close · Aug 14
Market Cap
$3.29B
Shares
125.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.19
Open$25.39
Day$25.28–26.24
52W close$15.32–31.20
Avg vol 30d1.5M
Short int12.7M · 10.1% float · 10.7d
Short vol33%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Oct 31, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−1%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
68%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
0%
trailing
YTD return
−10%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $26 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +43 funds added
Insider flow
Distributing
Net -$394.9K over 90 days · 100% sells
Short interest
Falling
10.09% of float · ▼ -6.5% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
270 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+91%
Y/Y
EPS growth
+89%
Y/Y
Free cash flow
$-6.3M
Balance sheet
$66.1M
net debt
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Net product sales
· 2026 full-year
$525M – $540M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
68%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $26 › 200d $26 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +43 funds added
Insider flow
Distributing
Net -$394.9K over 90 days · 100% sells
Short interest
Falling
10.09% of float · ▼ -6.5% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
270 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $15
Now $26 · 68%
Range high $31
vs 200-day avg +2%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash flow from operating activities | $12.6M | second quarter of 2026 | — |
|
|
|||
| ZORYVE cream 0.05% revenues | $2.9M | the quarter ended June 30, 2026 | — |
|
|
|||
| ZORYVE cream 0.15% revenues | $24.2M | the quarter ended June 30, 2026 | +65.6% |
|
|
|||
| ZORYVE cream 0.3% revenues | $35.3M | the quarter ended June 30, 2026 | +27.6% |
|
|
|||
| ZORYVE foam 0.3% revenues | $67.4M | the quarter ended June 30, 2026 | +71.9% |
|
|
|||
| ZORYVE net product sales | $129.9M | second quarter of 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARQT
this stock
Arcutis Biotherapeutics, Inc.
|
$3.29B | -9.8% | +91.3% | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARQT | +3.6% | -8.1% | -0.5% | -2.5% | -9.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +3.2% | -12.5% | -14.2% | -6.4% | -23.7% |
Key facts
CIK
1787306
CUSIP
03969K108
13F (30d)
266 filings
258 filers
Visit website
Investor relations